June 26, 2020 / 12:07 AM / 7 days ago

FDA approves Zogenix's drug for rare childhood epilepsy

June 25 (Reuters) - The U.S Food and Drug Administration on Thursday approved Zogenix Inc's drug to treat seizures associated with a rare form of childhood epilepsy known as Dravet syndrome. (reut.rs/3g2naBs)

The FDA last year had refused to fully review the marketing application for the treatment, and in February extended its review of the application by three months.

Dravet syndrome is a life-threatening, rare and chronic form of epilepsy, often characterized by severe and unrelenting seizures. (Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; editing by Uttaresh.V)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below